LONDON (Alliance News) - Vectura Group PLC said Friday its partner Ablynx NV has confirmed that it has completed patient enrolment in its Phase I/IIa safety study of its treatment for syncytial virus infection in infants, ALX-0171.
Ablynx is on track to publish top-line results in the first half of 2016, the company said. ALX-0171 is being developed by Anlynx and uses Vectura's nebuliser technology device, FOX, to deliver the treatment to patients.
Additionally, Ablynx also received a positive recommendation from an independent data monitoring committee based on data from the first 15 infants in the study, and following this recommendation the age requirements for infants in the trial has been reduced from three months to one month.
Shares in Vectura were up 0.1% at 171.90 pence Friday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
